CytoDyn and QLHC advance leronlimab into two new PRE-I-SPY studies in metastatic triple-negative breast cancer
CYDY•CytoDyn and QLHC are advancing leronlimab into two new PRE-I-SPY studies in metastatic triple-negative breast cancer. Enrollment is expected in PRE5 in the first quarter of 2027 and in PRE7 in the second or third quarter of 2027.
1. Enrollment timeline
CytoDyn and QLHC are advancing leronlimab into two new PRE-I-SPY studies in metastatic triple-negative breast cancer. Enrollment for PRE5 is expected in the first quarter of 2027, while PRE7 enrollment is expected in the second or third quarter of 2027.
